LifeVantage Co. (NASDAQ:LFVN) Short Interest Down 5.4% in December

LifeVantage Co. (NASDAQ:LFVN) saw a significant decline in short interest in December. As of December 31st, there was short interest totalling 191,800 shares, a decline of 5.4% from the December 15th total of 202,800 shares. Currently, 1.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 110,600 shares, the short-interest ratio is currently 1.7 days.

Institutional Investors Weigh In On LifeVantage

Several institutional investors and hedge funds have recently made changes to their positions in LFVN. Capital Management Corp VA acquired a new stake in LifeVantage in the third quarter valued at approximately $5,073,000. HighTower Advisors LLC bought a new position in shares of LifeVantage in the 3rd quarter worth $638,000. Ritholtz Wealth Management increased its stake in LifeVantage by 65.2% during the 4th quarter. Ritholtz Wealth Management now owns 47,348 shares of the company’s stock valued at $830,000 after purchasing an additional 18,682 shares in the last quarter. Renaissance Technologies LLC raised its holdings in LifeVantage by 2.1% during the second quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock worth $5,490,000 after buying an additional 17,300 shares during the last quarter. Finally, Barclays PLC lifted its stake in shares of LifeVantage by 38.2% in the third quarter. Barclays PLC now owns 41,966 shares of the company’s stock valued at $507,000 after buying an additional 11,608 shares in the last quarter. Institutional investors own 35.32% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Lake Street Capital started coverage on shares of LifeVantage in a research report on Thursday, December 19th. They set a “buy” rating and a $26.00 price objective for the company. Craig Hallum started coverage on shares of LifeVantage in a report on Tuesday, January 14th. They set a “buy” rating and a $35.00 price target for the company.

LifeVantage Price Performance

LifeVantage stock opened at $25.31 on Monday. The business has a 50 day moving average of $16.74 and a 200-day moving average of $12.16. The company has a market capitalization of $316.88 million, a P/E ratio of 79.10 and a beta of 0.82. LifeVantage has a 1 year low of $5.22 and a 1 year high of $27.38.

LifeVantage (NASDAQ:LFVN) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.15 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.15. The business had revenue of $47.21 million during the quarter. LifeVantage had a return on equity of 29.24% and a net margin of 2.11%.

LifeVantage Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were given a dividend of $0.04 per share. The ex-dividend date was Monday, December 2nd. This represents a $0.16 dividend on an annualized basis and a yield of 0.63%. LifeVantage’s dividend payout ratio (DPR) is currently 50.00%.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.